The biotech company Zymvol, a member of CATALONIA.HEALTH, has raised a seed funding of €3M. It was led by venture capital firms Faber Ventures (lead investor), Elaia Partners (existing pre-seed investor), and Übermorgen Ventures.
The Hospital Sant Joan de Déu Barcelona and Oxolife have received the CATALONIA.HEALTH 2025 Award (formerly Bioèxit) during the 11th edition of the Nit, the annual event of reference in the field of health and life sciences in Catalonia, organised by CATALONIA.HEALTH and life sciences in Catalonia, organised by CATALONIA.HEALTH. The award recognises relevant trajectories and projects based on the axes of innovation, science and business, and which stand out for their excellence in areas such as scientific innovation, industrialization innovation, industrialisation, regulatory milestones and international expansion.
The Hospital Sant Joan de Déu Barcelona has been distinguished ...
La startup SocialDiabetes, membre de CATALONIA.HEALTH, anuncia una aliança estratègica amb l’empresa Listen.Doctor i la multinacional tecnològica Babel per introduir solucions avançades en intel·ligència artificial i tecnologies de monitoratge que estan transformant l’atenció sanitària
The technology centre Eurecat, a member of CATALONIA.HEALTH, will apply the new single-cell genomic technology to evaluate the health impact of a diet based on alternative protein sources and characterize cells from cultivated meat, thus moving towards precision nutrition
The venture capital company Inveready has acquired Enantia, a company specialized in contract research (CRO). Both companies are members of CATALONIA.HEALTH. The acquisition has been done through INVACO, one of the companies controlled by the venture capital fund Inveready Biotech IV.
The pharmaceutical company Bionure and the Hospital del Mar Research Institute, both members of CATALONIA.HEALTH, establish a strategic collaboration to transform the treatment landscape of neurodegenerative diseases, such as Amyotrophic Lateral Sclerosis (ALS) or Epilepsy, with RNA therapies.
After several years participating laterally at the Mobile World Congress (MWC), the largest and most influential event on connectivity worldwide, and at 4YFN, the parallel event to the MWC of reference for the international entrepreneurial ecosystem, CATALONIA.HEALTH lands at the 2025 edition with a stand that will allow to present, in an interactive way, medical technologies from 8 companies' members.
The venture capital company Asabys Partners, a member of CATALONIA.HEALTH, co-leads a $50 million funding round for the biotechnology company Quibim.
The venture capital company Ship2B Ventures, a member of CATALONIA.HEALTH, created a financing round with the European consortium formed with LUMO Labs through its BSocial Impact Fund to obtain funding for the technology startup Sycai Medical.
The biotech company Aptadel Therapeutics, a member of CATALONIA.HEALTH, has announced a partnership with the Little Warrior Foundation. The foundation, based in the United States, will provide $500,000 in funding for its therapeutic programme against Ewing's sarcoma, specifically for the pre-clinical phases.
The biopharmaceutical company HIPRA, a member of CATALONIA.HEALTH, launches HIPRA Biotech Services, its new unit aimed at offering development and manufacturing services of biological products to companies in the biotechnology and pharmaceutical sectors. HIPRA Biotech Services covers the entire life cycle of the product, from the initial phases of research and development to production on a commercial scale.
Triana, a company specialised in packaging and manufacturing of plastic containers for the pharmaceutical industry and a member of CATALONIA.HEALTH, announces its participation in two key events in the packaging sector, Pharmapack and Paris Packaging Week 2025, which will take place in the city of Paris during the month of January.
The pharmaceutical company Almirall, a member of CATALONIA.HEALTH, announced at the JPMorgan HealthCare 2025 Conference, an update of its strategy and business perspectives.
Medical technology company Vitalera, a member of CATALONIA.HEALTH, achieved a significant milestone by successfully completing the rigorous re-classification process to MDR Class IIa certification.
The venture capital company Invivo Partners, a member of CATALONIA.HEALTH, announced the closing of a €20 million Series A financing round for the biotechnology company Neumirna Therapeutics.
El medicament ABTL0812, desenvolupat per Ability Pharma, empresa biotecnològica associada a CataloniaBio i especialitzada en el desenvolupament de fàrmacs en oncologia, ha obtingut la designació de medicament orfe per part de la Food and Drug Administration (FDA) als Estats Units. Aquesta designació, que es dóna als medicaments destinats a tractar malalties rares que afecten a menys de 200.000 persones als EUA, ara permetrà a Ability Pharma tenir set anys d'exclusivitat en el mercat d'aquest fàrmac, i facilitats en el procés d'aprovació del fàrmac i assessorament en el desenvolupament clínic.
L'ABTL0812 està destinat al tractament del càncer pancreàtic, una malaltia potencialment mortal amb necessitats mèdiques no cobertes, per la que les opcions de tractament són molt limitades a causa de la seva mala resposta a la quimioteràpia i la radioteràpia. La molècula ABTL0812 ha demostrat eficàcia contra el càncer de pàncrees com a agent únic i provoca la reducció dels tumors sense augmentar la toxicitat associada a la quimioteràpia. Actualment, el fàrmac es troba en la fase 2 com a tractament de primera línia en combinació amb quimioteràpia en pacients amb càncer de pulmó escatós o d'endometri al Vall d'Hebron Institut d'Oncologia (VHIO) i a l'Institut Català d'Oncologia (ICO) de Barcelona.
Podeu ampliar aquesta informació al web d'Ability Pharma.
Foto: Equip d'Ability Pharma.
Cookies settings
We collect and process your personal information for the following purposes: Analytics, Security & Marketing.
Comments